Charles River Laboratories International, Inc. announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex Limited, an innovator in pathology AI. By combining Deciphex?s unique digital pathology solutions with Charles River?s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment. In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.

By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work. Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse. Built on Patholytix 4.0, Deciphex's flagship non-clinical workflow, the tool integrates these AI classifiers with Whole Slide Images (WSI) to enhance and accelerate a pathologist?s decision-making by streamlining workflows for identifying critical features in specific tissues.